Genervon Biopharmaceuticals, LLC   Report issue

For profit Phase 2
Founded: Pasadena CA United States (1996)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2011
NCT01221246
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

gm602 (1 trial)

gm604 (1 trial)

gm608 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Parkinson Disease (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3